NASDAQ:HTBX

Heat Biologics Stock Forecast, Price & News

$6.47
-0.11 (-1.67 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.26
Now: $6.47
$6.60
50-Day Range
$6.58
MA: $7.84
$9.20
52-Week Range
$3.50
Now: $6.47
$30.10
Volume379,700 shs
Average Volume2.20 million shs
Market Capitalization$164.40 million
P/E RatioN/A
Dividend YieldN/A
Beta0.32
Heat Biologics, Inc., a biopharmaceutical company, focuses on developing immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. The company's T-cell activation platform, includes two variations for intradermal administration, such as immune pan-antigen cytotoxic therapy, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and combination pan-antigen cytotoxic therapy, a dual-acting immunotherapy, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. It is developing HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer. The company's preclinical stage products include HS-130 for the treatment of advanced solid tumors; PTX-35, a humanized affinity matured monoclonal antibody, which is a functional agonist of human TNFRSF25 signaling; and PTX-45, a human TL1A-Ig fusion protein that acts as an agonist of TNFRSF25 signaling. Heat Biologics, Inc. has collaboration with Waisman Biomanufacturing to manufacture COVID-19 Vaccine. The company was founded in 2008 and is headquartered in Morrisville, North Carolina.
Heat Biologics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HTBX
CUSIPN/A
Phone919-240-7133
Employees36
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.05 million
Book Value$2.73 per share

Profitability

Net Income$-20,020,000.00
Net Margins-527.90%

Miscellaneous

Market Cap$164.40 million
Next Earnings Date5/21/2021 (Estimated)
OptionableNot Optionable

Headlines

HTBX: Cash, COVID and Clinical Data
April 14, 2021 |  finance.yahoo.com
HTBX: HS-110 Phase 2 Interim Data
February 16, 2021 |  finance.yahoo.com
Is Heat Biologics Stock a Buy Right Now? Analyst Weighs In
February 10, 2021 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

1.59 out of 5 stars

Medical Sector

394th out of 2,024 stocks

Pharmaceutical Preparations Industry

186th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
$6.47
-0.11 (-1.67 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HTBX News and Ratings via Email

Sign-up to receive the latest news and ratings for HTBX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Heat Biologics (NASDAQ:HTBX) Frequently Asked Questions

Is Heat Biologics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Heat Biologics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Heat Biologics stock.
View analyst ratings for Heat Biologics
or view top-rated stocks.

What stocks does MarketBeat like better than Heat Biologics?

Wall Street analysts have given Heat Biologics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Heat Biologics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Heat Biologics' next earnings date?

Heat Biologics is scheduled to release its next quarterly earnings announcement on Friday, May 21st 2021.
View our earnings forecast for Heat Biologics
.

How were Heat Biologics' earnings last quarter?

Heat Biologics, Inc. (NASDAQ:HTBX) posted its quarterly earnings results on Thursday, November, 15th. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.05. The biopharmaceutical company had revenue of $1.84 million for the quarter, compared to the consensus estimate of $1.50 million. Heat Biologics had a negative net margin of 527.90% and a negative trailing twelve-month return on equity of 44.07%.
View Heat Biologics' earnings history
.

How has Heat Biologics' stock price been impacted by COVID-19?

Heat Biologics' stock was trading at $0.70 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, HTBX stock has increased by 824.3% and is now trading at $6.47.
View which stocks have been most impacted by COVID-19
.

When did Heat Biologics' stock split? How did Heat Biologics' stock split work?

Shares of Heat Biologics reverse split before market open on Monday, January 22nd 2018. The 1-10 reverse split was announced on Friday, January 19th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 19th 2018. An investor that had 100 shares of Heat Biologics stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for HTBX?

4 Wall Street analysts have issued 1-year target prices for Heat Biologics' shares. Their forecasts range from $4.00 to $40.00. On average, they expect Heat Biologics' share price to reach $20.00 in the next year. This suggests a possible upside of 209.1% from the stock's current price.
View analysts' price targets for Heat Biologics
or view top-rated stocks among Wall Street analysts.

Who are Heat Biologics' key executives?

Heat Biologics' management team includes the following people:
  • Mr. Jeffrey Alan Wolf, Founder, Chairman, CEO & Pres (Age 58, Pay $808.23k)
  • Mr. William L. Ostrander, CFO & Controller (Age 53, Pay $230.62k)
  • Dr. Justin Stebbing M.D., M.A., FRCP, FRCPath, Ph.D., Chief Medical Advisor and Member of Scientific & Clinical Advisory Board
  • Colonel George E. Peoples Jr., F.A.C.S., M.D., FACS, Chief Medical Advisor

Who are some of Heat Biologics' key competitors?

What other stocks do shareholders of Heat Biologics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heat Biologics investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Vaxart (VXRT), Bionano Genomics (BNGO), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), ADMA Biologics (ADMA), Novan (NOVN) and VBI Vaccines (VBIV).

What is Heat Biologics' stock symbol?

Heat Biologics trades on the NASDAQ under the ticker symbol "HTBX."

How do I buy shares of Heat Biologics?

Shares of HTBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Heat Biologics' stock price today?

One share of HTBX stock can currently be purchased for approximately $6.47.

How much money does Heat Biologics make?

Heat Biologics has a market capitalization of $164.40 million and generates $3.05 million in revenue each year.

How many employees does Heat Biologics have?

Heat Biologics employs 36 workers across the globe.

What is Heat Biologics' official website?

The official website for Heat Biologics is www.heatbio.com.

Where are Heat Biologics' headquarters?

Heat Biologics is headquartered at 627 DAVIS DRIVE SUITE 400, MORRISVILLE NC, 27560.

How can I contact Heat Biologics?

Heat Biologics' mailing address is 627 DAVIS DRIVE SUITE 400, MORRISVILLE NC, 27560. The biopharmaceutical company can be reached via phone at 919-240-7133 or via email at [email protected]


This page was last updated on 4/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.